# US 2016/0355469 A1 · Anticonvulsant compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2016/0355469 A1 - Document ID: US20160355469A1 - Status: Published application - Kind: A1 - Application number: 15/174,099 - Filed: 2016-06-06 - Published: 2016-12-08 - Earliest claimed: 2015-06-05 - Assignees: Owen-Barry Pharmaceuticals Inc. - Applicants: Owen-Barry Pharmaceuticals Inc. - Inventors: Michael Poulter; TONY DURST - Web page: https://patentgrep.com/patent/US20160355469A1 ## CPC - C07C 255/31: having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings - A61P 25/04: Centrally acting analgesics, e.g. opioids - A61P 25/08: Antiepileptics; Anticonvulsants - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07C 2601/02: with a three-membered ring - C07C 2601/16: the ring being unsaturated - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present application relates to compounds and methods for reducing the severity of convulsant activity, or epileptic seizures. ## Claims ### Claim 1 A compound represented by the following formula (I): wherein, R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, cC6H11, CH=CH2, or CH2Ar, R1=R2=H or CH3, R3=R4=H or CH3, R5=H, CH3, OCH3, OCH2Ar, Cl, or Br, and R6=H or CH3. ### Claim 2 (depends on 1) The compound of claim 1, wherein R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, or cC6H11. ### Claim 3 (depends on 2) The compound of claim 2, wherein R5=H or CH3. ### Claim 4 (depends on 3) The compound of claim 3, wherein R=H, CH3, or C2 to C6 (linear or branched). ### Claim 5 (depends on 4) The compound of claim 4, wherein R=H or CH3. ### Claim 6 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 7 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile. ### Claim 8 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile. ### Claim 9 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 10 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 11 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 12 (depends on 1) The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 13 A pharmaceutical composition for reducing the severity of convulsant activity, comprising a compound represented by the following formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient: wherein, R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, cC6H11, CH=CH2, or CH2Ar, R1=R2=H or CH3, R3=R4=H or CH3, R5=H, CH3, OCH3, OCH2Ar, Cl, or Br, and R6=H or CH3. ### Claim 14 (depends on 13) The pharmaceutical composition of claim 13, wherein R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, or cC6H11. ### Claim 15 (depends on 14) The pharmaceutical composition of claim 14, wherein R5=H or CH3. ### Claim 16 (depends on 15) The pharmaceutical composition of claim 15, wherein R=H, CH3, or C2 to C6 (linear or branched). ### Claim 17 (depends on 16) The pharmaceutical composition of claim 16, wherein R=H or CH3. ### Claim 18 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 19 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile. ### Claim 20 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile. ### Claim 21 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 22 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 23 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 24 (depends on 13) The pharmaceutical composition of claim 13, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 25 A method for reducing the severity of convulsant activity, comprising administering to a subject a therapeutically effective amount of a compound represented by the following formula (I): wherein, R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, cC6H11, CH=CH2, or CH2Ar, R1=R2=H or CH3, R3=R4=H or CH3, R5=H, CH3, OCH3, OCH2Ar, Cl, or Br, and R6=H or CH3. ### Claim 26 (depends on 25) The method of claim 25, wherein R=H, CH3, C2 to C6 (linear or branched), cC3H5, cC5H9, or cC6H11. ### Claim 27 (depends on 26) The method of claim 26, wherein R5=H or CH3. ### Claim 28 (depends on 27) The method of claim 27, wherein R=H, CH3, or C2 to C6 (linear or branched). ### Claim 29 (depends on 28) The method of claim 28, wherein R=H or CH3. ### Claim 30 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 31 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is 2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)pentanenitrile. ### Claim 32 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is 3-methyl-2-(3,5,5-trimethylcyclohex-2-en-1-ylidene)butanenitrile. ### Claim 33 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 34 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 35 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is a compound represented by the following formula: ### Claim 36 (depends on 25) The method of claim 25, wherein the compound represented by the formula (I) is a compound represented by the following formula: